九洲药业2月25日获融资买入1868.22万元，融资余额4.42亿元

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical has shown a stable financial performance with a slight increase in stock price and trading volume, indicating potential investor interest [1][2]. - As of February 25, Jiuzhou Pharmaceutical's financing balance is 442 million yuan, which accounts for 2.79% of its market capitalization, indicating a low level of financing compared to the past year [1]. - The company reported a revenue of 4.16 billion yuan for the period from January to September 2025, representing a year-on-year growth of 4.92%, while the net profit attributable to shareholders increased by 18.51% to 748 million yuan [2]. Group 2 - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders increased by 10.22% to 59,200, while the average circulating shares per person decreased by 9.27% to 15,035 shares [2][3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 20.368 million shares, an increase of 7.8125 million shares compared to the previous period [3].